Leukemia

Treatment with an all-oral regimen led to three-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia, a subset of acute myeloid leukemia.

As Billy Bean, MLB VP, revealed a cancer diagnosis and Toronto Blue Jays sportscaster, Jamie Campbell showed pre-skin cancer photo, here is what’s happening in the oncology space this week.

An expert discusses the FDA’s investigation into the possible association between CAR-T cell therapy and secondary T-cell malignancies.

Following promising study results, a Biologics License Application has been filed with the FDA for obe-cel (obecabtagene autoleucel), a CAR-T cell therapy for patients with relapsed/refractory (r/r) adult B-cell acute lymphoblastic leukemia (ALL).

The FDA announced rare instances of secondary diseases or cancers from CAR-T cell therapy, though this is not the first time that oncology treatments have been associated with secondary diseases.

In honor of National Family Caregiver’s Month, CURE® highlights some of the most important news in 2023.

An expert provided an overview of the promising therapies that are being investigated for the treatment of patients with chronic lymphocytic leukemia.

One doctor tells CURE why the FDA’s approval of the TKI Bosulif to treat children with chronic myelogenous leukemia “is really important.”

The FDA approved Bosulif for children aged 1 and older with newly diagnosed or resistant/intolerant chronic myelogenous leukemia.

After a stem cell donor saved the life of a patient with a rare leukemia, the two finally had a “very emotional” meeting this past spring in New York.

Patients with acute myeloid leukemia who took vitamin C and D supplements experienced fewer complications, but no overall survival benefits.

Iclusig plust reduced-intensity bested Gleevec when it came to MRD-negative complete remission in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

Elderly patients with acute myeloid leukemia did not experience a difference in relapse-free survival or non-relapse mortality with intensive versus non-intensive chemotherapy.

Survival outcomes and disparities for patients with blood cancers may depend on factors including insurance coverage, economic status and marital status.

Varying outcomes among adolescent and young adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia treated with pediatric-inspired protocols or adult chemotherapy regimens warrant further study.

MRD testing began among patients with chronic myeloid leukemia, a disease that lends itself to gauging MRD because it is driven by a specific genetic mutation.

Why minimal residual disease testing is the "gold standard" for some patients and providers.

Here’s a look back at blood cancer approvals from the summer of 2023.

I had acute myeloid leukemia in 2016 and tackled it with chemo. I had a recurrence in 2020 and tackled it with chemo and a bone marrow transplant.

As wide receiver John Metchie returns to the field after cancer experience, and coach Brent Venables announces wife’s cancer diagnosis, this is what’s happening in the oncology space this week.

As Ben Alldis reveals previous cancer diagnosis and Luke Combs brings a Make-a-Wish cancer survivor on stage during a concert venue, this is what’s occurring in the oncology space this week.

The Food and Drug Administration approved a Vanflyta regimen for patients with FLT-ITD—positive acute myeloid leukemia.

A recent study has determined that Xospata plus chemo is safe for the treatment of relapsed/refractory acute myeloid leukemia with an FLT3 mutation.

There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Lasting guilt gets no one anywhere — especially when it comes to cancer.

The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.

Three-fourths of patients with relapsed/refractory B-cell acute lymphoblastic leukemia experienced complete responses — which tended to be durable — when treated with the CAR-T cell therapy, Obe-cel.